1900 1717 
Customers can learn about their current health status by using the women’s tumor marker screening health package. Thus, timely intervention and treatment measures can be implemented to limit potentially fatal consequences.
1. Test package overview
The women’s tumor marker screening health package will aid in the early detection of cancers, even when no clinical symptoms exist. This can also be combined with the Overall health package – Basic (or Advanced) on a regular basis to broaden the screening scope of general health checks and help cancer patients monitor the effectiveness of treatment regimens.
2. Who should get testing?
The women’s tumor marker screening health package is for women aged 16 and up. Furthermore, this test panel can be administered to people who have no clinical symptoms or who have symptoms such as fever, fatigue, weight loss,… or other abnormal physical signs.
3. What’s measured?
The women’s tumor marker screening health package at Diag Laboratories includes:
- Alpha-Fetoprotein (AFP)*: cirrhosis screening
- CA 19-9: pancreas, bile
- CA 72-4: stomach
- Carcinoembryonic Antigen (CEA): colon and tumor markers screening of other cancers
- Cyfra 21-1 (Cytokeratin 19): non-small cell lung
- CA 125: ovary
- Squamous cell carcinoma (SCC): squamous cell, nasopharynx,…
- Thyroglobulin: thyroid
- CA 15-3: breast
4. What Do Test Indicators Mean?
- Alpha-Fetoprotein (AFP)*: This test can measure the level of AFP in the blood to screen for liver damage. It can be used during pregnancy to evaluate the fetus’s neural tube and spinal abnormalities.
- CA 19-9: Quantitative test to screen for abnormalities related to the pancreas and bile in the body
- CA 72-4: Stomach-related abnormalities screening
- Carcinoembryonic Antigen (CEA): Quantitative test to screen for abnormalities related to the colon and other organs in the body
- Cyfra 21-1 (Cytokeratin 19): Quantitative test to screen for non-small cell lung abnormalities
- CA 125: Quantitative test of CA 125 protein levels in the blood to screen and monitor ovarian cancer
- Squamous cell carcinoma (SCC): Quantitative test to screen for and monitor squamous cell carcinoma, nasopharyngeal carcinoma, and other cancers
- Thyroglobulin: Quantitative test of thyroglobulin levels to monitor and evaluate the effectiveness of treatment in patients with thyroid cancer
- CA 15-3: The cancer antigen 15-3 (CA 15.3) test is used to assess the efficacy of treatment response in breast cancer patients and the recurrence
5. Frequently asked questions about the women’s tumor marker screening test
- Who needs to carry out a test package for female cancer markers?
This health package is eligible for women aged 16 years and over, and no symptoms are required. Or when there are unusual symptoms such as headache, fever, weight loss, …
- Does the patient need to fast before sampling?
The answer is no.
- How long does it take to get test results?
It has taken about 3 hours since the Lab received the samples.
6. Why test at Diag Laboratories?
Diag has cutting-edge analysis systems such as Alinity (Abbott), Cobas 8000 (Roche), and others to ensure the quickest and most accurate results. Furthermore, Diag Laboratories offers a wide range of tests to aid in the diagnosis of a wide range of diseases.
Diag also offers a convenient home sampling and online result SMS service to save you time and effort.
When experiencing unusual symptoms, please contact Diag Laboratories immediately at 1800 1717 for advice and prompt treatment.